207 related articles for article (PubMed ID: 26448623)
1. Accelerated Telomere Shortening in Acromegaly; IGF-I Induces Telomere Shortening and Cellular Senescence.
Matsumoto R; Fukuoka H; Iguchi G; Odake Y; Yoshida K; Bando H; Suda K; Nishizawa H; Takahashi M; Yamada S; Ogawa W; Takahashi Y
PLoS One; 2015; 10(10):e0140189. PubMed ID: 26448623
[TBL] [Abstract][Full Text] [Related]
2. The GH-IGF-I axis and the cardiovascular system: clinical implications.
Colao A
Clin Endocrinol (Oxf); 2008 Sep; 69(3):347-58. PubMed ID: 18462260
[TBL] [Abstract][Full Text] [Related]
3. The effects of long-term growth hormone and insulin-like growth factor-1 exposure on the development of cardiovascular, cerebrovascular and metabolic co-morbidities in treated patients with acromegaly.
Jayasena CN; Comninos AN; Clarke H; Donaldson M; Meeran K; Dhillo WS
Clin Endocrinol (Oxf); 2011 Aug; 75(2):220-5. PubMed ID: 21521288
[TBL] [Abstract][Full Text] [Related]
4. Telomeres and endocrine dysfunction of the adrenal and GH/IGF-1 axes.
Aulinas A; Ramírez MJ; Barahona MJ; Mato E; Bell O; Surrallés J; Webb SM
Clin Endocrinol (Oxf); 2013 Dec; 79(6):751-9. PubMed ID: 23937625
[TBL] [Abstract][Full Text] [Related]
5. Age-dependent impairment of endothelial progenitor cells is corrected by growth-hormone-mediated increase of insulin-like growth-factor-1.
Thum T; Hoeber S; Froese S; Klink I; Stichtenoth DO; Galuppo P; Jakob M; Tsikas D; Anker SD; Poole-Wilson PA; Borlak J; Ertl G; Bauersachs J
Circ Res; 2007 Feb; 100(3):434-43. PubMed ID: 17234973
[TBL] [Abstract][Full Text] [Related]
6. The relationship between 24-hour growth hormone secretion and insulin-like growth factor I in patients with successfully treated acromegaly: impact of surgery or radiotherapy.
Peacey SR; Toogood AA; Veldhuis JD; Thorner MO; Shalet SM
J Clin Endocrinol Metab; 2001 Jan; 86(1):259-66. PubMed ID: 11232010
[TBL] [Abstract][Full Text] [Related]
7. Assessment of disease activity in treated acromegalic patients using a sensitive GH assay: should we achieve strict normal GH levels for a biochemical cure?
Costa AC; Rossi A; Martinelli CE; Machado HR; Moreira AC
J Clin Endocrinol Metab; 2002 Jul; 87(7):3142-7. PubMed ID: 12107214
[TBL] [Abstract][Full Text] [Related]
8. Diagnostic value of the acid-labile subunit in acromegaly: evaluation in comparison with insulin-like growth factor (IGF) I, and IGF-binding protein-1, -2, and -3.
Arosio M; Garrone S; Bruzzi P; Faglia G; Minuto F; Barreca A
J Clin Endocrinol Metab; 2001 Mar; 86(3):1091-8. PubMed ID: 11238491
[TBL] [Abstract][Full Text] [Related]
9. Critical telomere shortening regulated by the ataxia-telangiectasia gene acts as a DNA damage signal leading to activation of p53 protein and limited life-span of human diploid fibroblasts. A review.
Vaziri H
Biochemistry (Mosc); 1997 Nov; 62(11):1306-10. PubMed ID: 9467855
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of disease status with sensitive measures of growth hormone secretion in 60 postoperative patients with acromegaly.
Freda PU; Post KD; Powell JS; Wardlaw SL
J Clin Endocrinol Metab; 1998 Nov; 83(11):3808-16. PubMed ID: 9814451
[TBL] [Abstract][Full Text] [Related]
11. Influence of growth hormone receptor d3 and full-length isoforms on biochemical treatment outcomes in acromegaly.
Bianchi A; Giustina A; Cimino V; Pola R; Angelini F; Pontecorvi A; De Marinis L
J Clin Endocrinol Metab; 2009 Jun; 94(6):2015-22. PubMed ID: 19336510
[TBL] [Abstract][Full Text] [Related]
12. Secondary diabetes associated with principal endocrinopathies: the impact of new treatment modalities.
Resmini E; Minuto F; Colao A; Ferone D
Acta Diabetol; 2009 Jun; 46(2):85-95. PubMed ID: 19322513
[TBL] [Abstract][Full Text] [Related]
13. Dynamic tests and basal values for defining active acromegaly.
Tzanela M
Neuroendocrinology; 2006; 83(3-4):200-4. PubMed ID: 17047383
[TBL] [Abstract][Full Text] [Related]
14. Associations between body composition, circulating interleukin-1 receptor antagonist, osteocalcin, and insulin metabolism in active acromegaly.
Ueland T; Fougner SL; Godang K; Lekva T; Schurgers LJ; Scholz H; Halvorsen B; Schreiner T; Aukrust P; Bollerslev J
J Clin Endocrinol Metab; 2010 Jan; 95(1):361-8. PubMed ID: 19880791
[TBL] [Abstract][Full Text] [Related]
15. Change of telomere length in angiotensin II-induced human glomerular mesangial cell senescence and the protective role of losartan.
Feng X; Wang L; Li Y
Mol Med Rep; 2011; 4(2):255-60. PubMed ID: 21468560
[TBL] [Abstract][Full Text] [Related]
16. Octreotide as primary therapy for acromegaly.
Newman CB; Melmed S; George A; Torigian D; Duhaney M; Snyder P; Young W; Klibanski A; Molitch ME; Gagel R; Sheeler L; Cook D; Malarkey W; Jackson I; Vance ML; Barkan A; Frohman L; Kleinberg DL
J Clin Endocrinol Metab; 1998 Sep; 83(9):3034-40. PubMed ID: 9745397
[TBL] [Abstract][Full Text] [Related]
17. IGF-I enhances cellular senescence via the reactive oxygen species-p53 pathway.
Handayaningsih AE; Takahashi M; Fukuoka H; Iguchi G; Nishizawa H; Yamamoto M; Suda K; Takahashi Y
Biochem Biophys Res Commun; 2012 Aug; 425(2):478-84. PubMed ID: 22877754
[TBL] [Abstract][Full Text] [Related]
18. Human skin fibroblast telomeres are shortened after ultraviolet irradiation.
Ma HM; Liu W; Zhang P; Yuan XY
J Int Med Res; 2012; 40(5):1871-7. PubMed ID: 23206469
[TBL] [Abstract][Full Text] [Related]
19. Usefulness of different biochemical markers of the insulin-like growth factor (IGF) family in diagnosing growth hormone excess and deficiency in adults.
Marzullo P; Di Somma C; Pratt KL; Khosravi J; Diamandis A; Lombardi G; Colao A; Rosenfeld RG
J Clin Endocrinol Metab; 2001 Jul; 86(7):3001-8. PubMed ID: 11443159
[TBL] [Abstract][Full Text] [Related]
20. Chronic growth hormone excess is associated with increased aldosterone: a study in patients with acromegaly and in growth hormone transgenic mice.
Bielohuby M; Roemmler J; Manolopoulou J; Johnsen I; Sawitzky M; Schopohl J; Reincke M; Wolf E; Hoeflich A; Bidlingmaier M
Exp Biol Med (Maywood); 2009 Aug; 234(8):1002-9. PubMed ID: 19491373
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
